Should You Invest in Teladoc After Its Post-Earnings Dip?
This week, shares of Teladoc Health (NYSE: TDOC) slid to a new 52-week low of less than $134 per share. This comes on the heels of the company's first-quarter earnings report, which came out on April 28. Although the performance it reflected wasn't horrible, investors may have been expecting more from the business, which had an incredible year in 2020 with demand for telehealth services soaring. The bar was set high, and that is going to make 2021 all the more challenging for Teladoc to impress investors.
But now that chronic-care company Livongo is part of its business, Teladoc will still have plenty of growth opportunities. With the healthcare stock trading at its lowest price in more than a year, should investors consider buying shares of Teladoc or is there still more pain to come?
Image source: Getty Images.
Source Fool.com
